Look at the authorized of most biotechs. As it stands completing phase 2 will most likely cost 30 million dollars. If they are successful in phase 2 this could be a blockbuster drug. In addition to depression there are also very good peer reviews for pain, Hodgkinson and Parkinson's.
Phase 2a is being funded completely by the NIH, no small feat.
The people in the company are first rate and the facilities conducting the trials are first rate.
News 
Market Data 
Discover 
